RxDoctor Payments Data

Jose Gonzalez-Canal, MD

Psychiatry · Port Charlotte, FLNPI 1285606558

Payments from drug & device makers

$4,017in general payments, 2019–2025

Across 189 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$724
  • Otsuka America Pharmaceutical, Inc.$595
  • AbbVie$548
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$386
  • Teva Pharmaceuticals USA, Inc.$358
  • Merck$233
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,94398%
  • Education$742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,017 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$159,768
Medicare patients
491
Services billed
1,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$120,684
AustedoDeutetrabenazine13$82,015
VraylarCariprazine Hcl42$68,318
Invega SustennaPaliperidone Palmitate12$27,712
TrintellixVortioxetine Hydrobromide25$17,923
BelsomraSuvorexant25$12,990
Alprazolam1,517$9,356
Quetiapine Fumarate362$9,181
Clonazepam939$8,177
Venlafaxine Hcl ErVenlafaxine Hcl306$7,580
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine195$6,816
Duloxetine Hcl185$6,797
VyvanseLisdexamfetamine Dimesylate15$5,873
Aripiprazole136$5,852
Trazodone Hcl432$5,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$63$120,68413 claims
Teva Pharmaceuticals USA, Inc.Austedo$358$82,01513 claims
AbbVieVraylar$548$68,31842 claims
Johnson & JohnsonInvega Sustenna, Concerta$17$32,37023 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$92$23,79540 claims
MerckBelsomra$233$12,99025 claims
Almatica Pharma LLCSertraline Hcl$62$2,043209 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →